Opendata, web and dolomites

WASABI

Towards the Wider uptake of Arterial Stiffness As a BIomarker for cardiovascular diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 WASABI project word cloud

Explore the words cloud of the WASABI project. It provides you a very rough idea of what is the project "WASABI" about.

alam    plan    complicate    technologies    demonstration    elevated    questionable    arteriograph    niche    predict    business    individuals    create    everyday    lower    undertaking    relatively    affordable    pressure    physicians    aortic    distribute    population    of    stage    device    recognised    shown    select    property    sensor    pulsepen    cardiologists    pwv    biomarker    graph    mellitus    renal    carotid    either    hypertension    arterial    mo    assemble    appropriate    mortality    intellectual    stiffness    measuring    notably    methodology    mainly    model    sphygmocor    actions    alternative    secure    vasotens    gold    transform    sensors    innovation    suitable    standard    pulse    intend    stiffening    contexts    initiated    rights    clinical    serial    bil    velocity    market    elaborate    wave    diabetes    estimations    expensive    easier    move    tool    local    artery    practitioners    signal    medical    bplab    cardiovascular    complior    blood   

Project "WASABI" data sheet

The following table provides information about the project.

Coordinator
ALAM MEDICAL 

Organization address
address: 112 AVENUE DE PARIS
city: VINCENNES
postcode: 94300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.complior.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-12-01   to  2016-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALAM MEDICAL FR (VINCENNES) coordinator 50˙000.00

Map

 Project objective

Aortic stiffness is a recognised cardiovascular biomarker and measurement of aortic pulse wave velocity (PWV) is the gold standard methodology to assess large artery stiffening. Elevated aortic PWV has been shown to predict cardiovascular, and in some cases all cause, mortality in individuals with end-stage renal failure, hypertension, diabetes mellitus, as well as in the general population. However, at present, the role of measurement of PWV as a general clinical tool remains to be established, particularly because devices on the market (ALAM Medical Complior, SphygmoCor, Mo-bil-O-Graph, PulsePen, BPLab Vasotens, or Arteriograph) are either complicate to use and relatively expensive, or only provide lower cost estimations whose clinical value is questionable.

That’s why ALAM Medical has initiated an innovation project whose objective is to scale up the use of arterial stiffness as a biomarker, notably by investigating alternative sensors so as to create and distribute an easier to use and more affordable device measuring gold standard aortic stiffness and local carotid stiffness while being suitable for everyday use in numerous medical contexts. By providing a medical device with such characteristics, as well as by undertaking appropriate market awareness actions, we intend to transform our existing niche market, mainly composed of clinical researchers, into a large-scale market composed of clinical practitioners, cardiologists or physicians: arterial stiffness measurements have the potential to move from research to standard medical practice, on the model of blood pressure measurements.

To this aim, during project Phase 1, ALAM Medical will select the most appropriate sensor technology, secure intellectual property rights on sensor and signal processing technologies, assemble pre-serial devices, elaborate a more detailed business plan, and design a large-scale demonstration study (included in project Phase 2).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "WASABI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "WASABI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More